Colorectal Cancer

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

Michel Vulfovich, MD, medical director, Sickle Cell Disease and Gynecology Oncology programs, Memorial Healthcare System, discusses the utility of broad molecular profiling in metastatic colorectal cancer (mCRC).

The FDA has granted a priority review designation to a supplemental new drug application for the combination of encorafenib and cetuximab as a treatment for patients with advanced BRAF V600E­–mutant metastatic colorectal cancer following up to 2 prior lines of therapy.

Richard Kim, MD, discusses the use of immunotherapy in colorectal cancer.

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses treatment for patients with resectable colorectal cancer (CRC).

Cathy Eng, MD, FACP, FASCO, discusses ways to address unmet needs for young adults with colorectal cancer.

Richard Kim, MD, discusses how molecular profiling can be used to optimize outcomes in patients with metastatic colorectal cancer.

Ryan B. Corcoran, MD, PhD, discusses the utility of regorafenib in colorectal cancer.

Al B. Benson, MD, discusses the implications of microsatellite instability testing on patients with colorectal cancer.

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

Ryan B. Corcoran, MD, PhD, discusses promising combination strategies with immunotherapy in metastatic colorectal cancer.

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses ongoing research with immunotherapy in metastatic colorectal cancer (mCRC).

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

In a phase III trial, investigators are examining if arfolitixorin can supplant leucovorin calcium, a widely used component of combination regimens in patients with metastatic colorectal cancer.

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

Cathy Eng, MD, FACP, FASCO, discusses unique barriers facing patients with early-onset colorectal cancer.

Ryan B. Corcoran, MD, PhD, discusses emerging therapeutics for patients with relapsed/refractory colorectal cancer.

Lukas E. Dow, PhD, discusses ongoing research evaluating Wnt as a potential target in colorectal cancer.

Al B. Benson, MD, discusses personalized treatment strategies for patients with metastatic colorectal cancer.

Al B. Benson, MD, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer.

Overall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.

The investigational KRAS G12C inhibitor MRTX849 demonstrated clinical activity in patients with non–small cell lung cancer and colorectal cancer.

Luke Dow, PhD, discusses phase I trials targeting the Wnt signaling pathway in colorectal cancer.

Benjamin Weinberg, MD, discusses the treatment options available for the various subpopulations in metastatic colorectal cancer.